Introduction
Meta-analysis, which combines summary statistics from a series of independent studies, plays an increasingly important role in human genetics research. [1] [2] [3] Obtaining summary statistics is much more appealing than collecting individual participant data because it protects the privacy of study participants, avoids cumbersome integration of genotype and phenotype data from different studies, and increases the number of available studies. In addition, meta-analysis of summary statistics is statistically as efficient as joint analysis of individual participant data. 4, 5 Thus, meta-analysis has become a norm in GWASs, resulting in the discoveries of numerous common variants associated with complex human diseases. Recent advances in next-generation sequencing technologies have made it possible to extend association studies to rare variants, which are expected to have larger effects on complex human diseases than common variants. 6, 7 To enrich association signals and reduce the penalty of multiple testing, investigators typically perform gene-level association tests by aggregating the mutation information of the rare variants within a gene. The simplest approach is the burden test, which calculates a single burden score for each subject by taking a weighted sum of the mutation counts over the variant sites with weights dependent on minor allele frequencies (MAFs) and assesses the disease association with the burden score. [8] [9] [10] [11] [12] A second approach is the variable threshold (VT) method, which performs a burden test by aggregating the variants whose MAFs are lower than a threshold and minimizes the p value over observed MAF thresholds. 11, 12 A third approach is the variance-component testing, which is aimed at detecting the presence of both deleterious and protective variants in the same gene. [13] [14] [15] Gene-level tests for rare variants have limited power because only a small fraction of study subjects carry any mutation within a gene and there are high background rates of neutral variation even in ''causal'' genes. Thus, there is a growing recognition that identifying ''causal'' rare variants would require large-scale meta-analysis. It is much more challenging to perform meta-analysis of rare variants than to do so with common variants. First, different studies may adopt different types of gene-level tests, so the test results are not compatible. Second, even if the same type of test is adopted, different studies may use different gene annotations, different classes of variants, or different MAFs. Third, meta-analysis is restricted to the specific gene-level test results provided by the participating studies and there is no flexibility to perform other tests. Fourth, VT and variance-component tests are multivariate in nature, so the meta-analysis requires multivariate summary statistics (i.e., the components of the test statistic and their covariance matrix); combining the p values of multivariate tests would lose power. Although these difficulties may be alleviated by following a common protocol in a well-organized consortium, the tremendous effort required to execute such a protocol will seriously limit the use of meta-analysis.
To circumvent these problems, we propose to collate only the results of single-variant analysis from participating studies and leave the choices of the gene-level test, annotation, variant class, and MAFs to the discretion of the meta-analyst. This attractive strategy is possible because of two important insights. First, all commonly used gene-level test statistics can be constructed from the score vector and the corresponding information matrix for testing the global null hypothesis that none of the variants in the gene is associated with the disease phenotype. Second, the score vector and information matrix can be recovered from the single-variant results, namely the p values based on Wald, score, or likelihood-ratio (LR) tests and the effect estimates, together with the correlation matrix of the single-variant test statistics. The correlation matrix can be estimated from one of the participating studies, perhaps the study that the meta-analyst is directly involved with. If such a study is not available, the correlation matrix can be approximated by the correlation matrix of the genotypes from a publicly available database, such as the 1000 Genomes, HapMap, or NHLBI Exome Sequencing Project (ESP). [16] [17] [18] We show both theoretically and numerically that the proposed meta-analysis approach provides accurate control of the type I error and is as powerful as joint analysis of individual participant data. This approach can accommodate any disease phenotype and any study design and produce all commonly used gene-level tests. The proposed approach not only greatly facilitates metaanalysis of sequencing studies but also provides a way to exploit the massive GWAS data. Many GWASs have focused on common variants but have also produced single-variant results for rare and low-frequency variants, which have seldom been exploited. Our approach can be used to combine such single-variant results and perform gene-level association tests. Single-variant results are available in NCBI's database of Genotypes and Phenotypes (dbGaP) and can be freely accessed without applying for controlled access to individual participant data. Thus, the proposed approach is far more useful than any methods that require multivariate summary statistics or individual participant data.
This work was motivated by the GIANT project. 19, 20 The
GIANT consortium successfully identified a number of common variants for anthropometric traits. 19, 20 It also collected single-variant summary results for rare and lowfrequency variants. Single-variant meta-analysis of those results would have little power. Therefore, we wished to conduct gene-based meta-analysis for those variants. Because the consortium involved a very large number of cohorts, it would not be feasible to ask individual investigators to perform gene-level association tests and provide multivariate summary statistics. Therefore, we applied the proposed methods to the existing single-variant summary results by using one of the participating cohorts, the Atherosclerosis Risk in Communities (ARIC) Study, 21 as the internal reference. We identified several genes containing variants for extreme height that were not detectable by single-variant meta-analysis.
Material and Methods
Suppose that we are interested in m rare variants within a gene.
(We use the term ''rare variants'' to encompass both low-frequency and truly rare variants.) The genotypes are represented by G ¼ ðG 1 ; .; G m Þ T , where G j is the number of minor alleles at the j th variant site. Let Y denote the trait of interest, which can be continuous or discrete, and let X denote a set of covariates (e.g., demographical variables and principal components for ancestry) plus the unit component. We relate Y to G and X through a generalized linear model by specifying the conditional density function of Y given G and X as exp For a study with n unrelated subjects, the data consist of ðY i ; G i ; X i Þ ði ¼ 1; .; nÞ. The score statistic for testing the null hypothesis
where b g and b f are the restricted maximum likelihood estimators (MLEs) of g and f under H 0 . For the linear model,
Under H 0 , U is asymptotically m-variate normal with mean 0 and covariance matrix
which is the information matrix evaluated at 
Under H 0 , U is asymptotically m-variate normal with mean 0 and covariance matrix V. If we allow g and f of Equation 1 to be different among the L studies, then U is exactly the score statistic for testing H 0 in the joint likelihood of the individual participant data of the L studies. 5 Thus, meta-analysis based on score statistics is equivalent to joint analysis of individual participant data.
Given U and V, we can construct all commonly used gene-based association tests for rare variants. Specifically, define the (weighted) burden score x T G, where x is an m-vector of weights that depend on the MAFs. [8] [9] [10] [11] [12] The score statistic for testing the disease association with the burden score can be expressed as weight matrix that depends on the MAFs through a beta function. 15 The null distribution of Q is determined by P m j¼1 l j c The above meta-analysis approach is predicated on the availability of U and V for each study. Note that U is an m 3 1 vector and V is an m 3 m matrix. Such multivariate summary statistics are not available in published papers or public databases. Even for a well-organized consortium, it is logistically difficult to generate such multivariate summary statistics. We show below that it is possible to recover U and V for each study from the (univariate) single-variant statistics provided that the correlation matrix of U can be estimated from an internal or external reference panel.
For each study, let U j denote the j th component of U and ffiffiffiffiffiffi LR p , respectively, where b b j is the MLE of b j , se j is the standard error of b b j , and LR is the likelihood ratio statistic. The three forms of Z j are asymptotically equivalent. When U j is not available but Z j is, we approximate U j by
where w j is an approximation to
which is asymptotically m-variate normal with mean 0 and covariance matrix
.; mg, where
and R ¼ fR jl ; j; l ¼ 1; .; mg is the covariance or correlation matrix of ðZ 1 ; .; Z m Þ T . We substitute b U and b V for U and V in each study and perform the aforementioned gene-based association tests. If Z j is the score test and
however, meta-analysis based on b U and b V will still have correct type I error as long as the correlation matrix R is correctly estimated for each study.
We show in Appendix A that the correlation matrix R is determined primarily by the correlation matrix of G. Specifically, two studies with the same correlation matrix of G will have the same R if covariates are absent or independent of genotypes and will have approximately the same R even if covariates are correlated with genotypes. Thus, we can use the value of R from one study to approximate the values of R in other studies with similar linkage disequilibrium (LD) structures. We refer to such a study as the internal reference. If no internal reference is available, we resort to an external reference panel such as the HapMap, 1000 Genomes, or ESP. [16] [17] [18] It is desirable to use an internal or external reference panel that has the same ancestry as the target study to ensure similar LD structures. We assume that the summary statistics that are available for meta-analysis contain the parameter estimates and p values of individual variants, i.e., ð b b j ; p j Þ ðj ¼ 1; .; mÞ, for each study, where p j is the (two-sided) p value based on the Wald, score, or LR test. We recover the test statistic Z j by signð b b j ÞF À1 ð1 À p j =2Þ, where F is the standard-normal distribution function. (We replace p j =2 by p j in the formula if the p value is based on a one-sided test.) The standard error estimates se j s are usually contained in the summary results. If not, we recover se j by b b j =Z j . This approximation is exact if Z j is the Wald statistic and is accurate if Z j is the score or LR statistic. Recall that se j is the standard error estimate of b b j and that V jj is the variance estimate of U j . It is reasonable to set w j ¼ 1=se j because 1=se j is the same as V 1=2 jj except that the information matrix used to calculate se j is evaluated at the MLEs of b j , g, and f whereas the information matrix used to calculate V jj is evaluated at b ¼ 0 and the restricted MLEs of g and f. For rare variants, the se j s may be unstable. If an internal reference study is available, we may set .; Mg, where M is the total number of variants that are genotyped and se Ã l is the value of se l in the reference study. The median provides a stable estimate for the ratio of the two standard errors, allowing the trait variances or the case-control ratios to be different between studies. If no internal reference is available, we set w j ¼ ðse y j Þ À1 3 median l¼1;.;M ðse y l =se l Þ, where se y l is the value of se l in the largest study of the meta-analysis.
In short, the summary results contain minimally the p values and effect estimates, from which we recover the standard-normal statistics. The standard error estimates are optional. When they are not available, we set se j ¼ b b j =Z j . If an internal reference is available, we set w j ¼ V 
Results

Simulation Studies
We carried out extensive simulation studies to evaluate the performance of the proposed methods in realistic settings.
To cover different MAF and LD spectrums, we chose two genes on chromosome 1 (OR2T29 and LDLRAD1) and focused on SNPs with MAFs <5%. According to the WHI African-American data from the ESP, 18 there are seven Table 2 . This gene contains mostly rare SNPs, the correlations being very low except for one pair. We generated the SNP genotypes of the two genes via GWAsimulator 22 to mimic the MAFs and LD patterns observed in the ESP WHI data.
We conducted meta-analysis of three studies with 2,000, 1,500, and 1,000 subjects, referred to as study 1, study 2, and study 3, respectively. We considered the situations both with and without an internal reference. For the former, study 1 was treated as the internal reference. For the latter, we generated an ''external'' reference panel with 1,000 subjects (mimicking the ESP WHI data). We simulated quantitative traits from the linear regression model Y ¼ bS þ 0:2X þ e and binary traits from the logistic regression model logfPðY ¼ 1Þ=PðY ¼ 0Þg ¼ bS þ 0:2X, where S is the total number of mutations the subject carries in the gene, X is a normal random variable with mean 0.2S and variance one, and ε is zero-mean normal with variance s 2 . Note that X is correlated with S and may represent a principal component for ancestry. To allow the possibilities of both equal and unequal error variances among studies, we set s 2 ¼ 1:0 in study 1 and varied the values of s 2 in the other two studies. For binary traits, we obtained an equal number of cases and controls for study 1 and varied the case-control ratios for the other two studies. As shown in Tables 1 and 2 , the correlation matrices of the test statistics are highly similar between the case-control ratios of 1 and 2 (middle and bottom blocks) and are also very similar to the correlation matrix of the genotypes in the external reference panel (upper block). These results corroborate the theoretical results given in Appendix A. We evaluated the proposed methods based on singlevariant statistics with an internal or external reference, denoted as SV-I and SV-E, respectively. As a benchmark, we included the meta-analysis method based on multivariate statistics (i.e., U and V), referred to as MV, which is a gold standard because it is equivalent to joint analysis of original data. We also included a naive method that sets w j to 1=se j and R to the identity matrix; the naive method assumes independence among variants and thus does not use any reference data to estimate the LD. We constructed the burden, VT, and SKAT tests. For the burden test, we adopted the MAF threshold of 5%, which is commonly called T5. For SKAT, we used the default weighted linear kernel function. We considered the p values from the Wald, score, and LR tests.
The type I error rates for quantitative and binary traits when the summary statistics contain the standard error estimates are shown in Tables 3 and 4 , respectively. The corresponding results when the summary statistics do not contain the standard error estimates are shown in Tables S1 and S2 available online. The two sets of results are highly similar. For quantitative traits, both SV-I and SV-E with the score, LR, or Wald test are as accurate as MV. For binary traits, SV-I tends to be more accurate than SV-E and the Wald test tends to be more conservative than the score and LR tests, especially for LDLRAD1. The naive method has severe inflation of the type I error, even for LDLRAD1, which has only one pair of correlated SNPs. Figures 1 and 2 compare the powers of SV-I, SV-E, and MV for quantitative and binary traits, respectively. The results of the naive method are not shown because it has inflated type I error and thus would not make a fair power comparison. For quantitative traits, both SV-I and SV-E are as powerful as MV. For binary traits, SV-I and SV-E tend to be slightly less powerful than MV; SV-E loses a little more power than does SV-I because the w j s in SV-E are not as stable as in SV-I. However, all the power differences are very small. The results for SV-I and SV-E shown in Figures  1 and 2 pertain to the score test. For quantitative traits, the results based on the Wald and LR tests are virtually identical to those of the score test (data not shown). For binary traits, the LR test yields slightly higher power than the score test whereas the Wald test yields slightly lower power; see Figures S1 and S2. The summary statistics include the standard error estimates. The nominal significance level a ¼ 0:001. Ratio is the case-control ratio in studies 2 and 3. MV is the gold standard. Each entry is based on 1,000,000 replicates.
We also compared our methods to Fisher's method of combining p values. As shown in Figure S3 , our methods are substantially more powerful than Fisher's method.
Finally, we examined the robustness of the proposed methods to misspecification of the reference. We simulated an external reference mimicking the HeartGO African-American data from the ESP while still simulating studies 1-3 from the ESP WHI data. In the HeartGO data, the eight SNPs in LDLRAD1 have MAFs of 0.011, 0, 0.001, 0.016, 0, 0.01, 0.001, and 0 and genotype correlations shown in Table S3 . Clearly, the MAFs and LD patterns differ considerably between the WHI and HeartGO data. The simulation results for the proposed method based on single-variant statistics with the misspecified external reference, denoted by SV-E 0 , are shown in Table S4 and Figure S4 . Evidently, SV-E 0 has reasonable control of the type I error and is slightly less powerful than SV-E (using the correct external reference).
GIANT Data
The GIANT consortium is an international collaboration that seeks to discover genetic loci that modulate human body size and shape, including height and measures of obesity. 19 The consortium was recently interested in identifying genetic loci associated with the extremes of height, body mass index (BMI), and waist-hip ratio adjusted by BMI. 20 The investigators from 50 GWASs were asked to perform case-control comparisons, treating individuals in the highest 5 th percentile of the age-and sexadjusted distribution as cases and those in the lowest 5 th percentile as controls, for a total of~2.8 million SNPs (genotyped or imputed by the HapMap CEU population); the analysis was stratified by sex and disease status and adjusted by age and principal components for ancestry. The summary results submitted to the consortium contain the effect estimates, the standard error estimates, and the two-sided p values of the association tests for individual SNPs. The associations with common SNPs had been assessed by single-variant metaanalysis; however, the information on rare variants had not yet been exploited because of the lack of proper analysis methods. With the proposed methods, we conducted gene-level association tests of rare variants through meta-analysis of the single-variant summary results, focusing on the binary trait of extreme height.
The 50 studies involved~160,000 cohort members of the European ancestry, among whom~14,600 subjects were selected as cases or controls for extreme height. The sample sizes ranged from 812 to 14,594, with a median of 13,413. We had access to the original data from one of the cohorts, the ARIC study, 21 which contains 8,108
cohort members and 812 subjects with extreme height. Because the subjects from the 50 studies are all of the same ancestry, we used the ARIC study as the internal reference. We annotated the genes in PLINK and filtered out SNPs with MAFs >5% to end up with 10,851 genes containing at least one SNP. Thus, the genome-wide significance threshold based on the Bonferroni correction would be~5 3 10 À6 . The qq-plots for the SV-I and naive methods are displayed in Figure 3 . The naive method yielded excessive positive findings and failed to identify some of the genes identified by the SV-I method. Although the values of the genomic control l were~1.1 for the SV-I tests, the modest inflation is unlikely attributed to the proposed methods because the value of l was~1.08 in the singlevariant meta-analysis (data not shown). The SV-I T5 tests identified seven genes that pass the genome-wide significance threshold of 5 3 10 À6 . The results for those genes are shown in Table 5 was reported. 19 None of the other genes in Table 5 
Discussion
We presented a simple strategy to perform meta-analysis of association results for rare variants in GWASs and sequencing studies. Our approach is very convenient and versatile because it requires only univariate statistics from standard single-variant analysis and accommodates any type of study and any type of trait. Our algorithms are very fast. It took~2 hr on an IBM HS22 machine to perform the meta-analysis of the GIANT data. The proposed methods are implemented in the software MAGA: MetaAnalysis of Gene-level Associations.
Alternative methods are being pursued independently by other research groups. To our knowledge, those methods all require multivariate statistics (i.e., the score vector U and the information matrix V). It is more challenging, both theoretically and computationally, to develop meta-analysis methods based on univariate statistics. We made a key observation that multivariate statistics can be recovered from univariate statistics provided that the correlation matrix of the single-variant test statistics can be determined. We rigorously justified the use of an internal or external reference to estimate the correlation matrix and derived statistically optimal and numerically stable weighting schemes. From a practical point of view, multivariate statistics can be collected only prospectively in well-organized consortia. By contrast, our approach requires only readily available univariate results from single-variant analysis and is particularly attractive in the retrospective analysis of existing studies.
Our approach requires a good estimate for the correlation matrix of the single-variant test statistics. We showed both theoretically and numerically that the correlation matrix of the test statistics is determined primarily by the correlation matrix of the genotypes and is not sensitive to the trait variance, the case-control ratio, or the distribution of covariates. The studies to be combined need not to be drawn from a single ancestral population. If the studies involve both European and African ancestries, then race-specific (internal or external) references can be used. It is preferable to use an internal than an external reference and to use a large reference panel.
Our methods allow variants to be polymorphic in only some of the participating studies by setting the entries in the score vector and information matrix corresponding to a nonpolymorphic variant to zero. In our current implementation, we disregard the variants that are not polymorphic in the reference panel. An alternative strategy is to assume that such rare variants are independent of others so that the corresponding entries in the correlation matrix R can be set to zero.
Meta-analysis based on score tests performs better than that of LR or Wald tests, especially for binary traits with rare variants. We make use of the standardized test statistics or p values rather than the score statistics (i.e., components of U) and their variances (i.e., diagonal elements of V). The latter, together with the correlation matrix, would completely recover the multivariate statistics. We do not require score statistics and their variances because they are not available in standard software packages such as SAS and R. However, score statistics and their variances can be obtained from special computer programs, such as SCORE-Seq 12 and SCORE-SeqTDS. 23 We recommend that such information be included in the summary results of single-variant analysis in the future, which will lead to more accurate meta-analysis. In the current practice, a variant that does not have a valid effect estimate is excluded from the summary results file. For a case-control study, the log odds ratio cannot be estimated if there are no mutations in either the case group or the control group. However, such a study contains valuable information about the association. To solve this dilemma, we again recommend that researchers include the score statistics and their variances in the summary results, which can be combined efficiently in meta-analysis. Another (less attractive) solution would be to report the p value of an asymptotic or exact test and the direction of the association. These two pieces of information can be used to construct an approximate standard-normal statistic, and the sample size and MAF can be used to estimate the variance for the weighting scheme.
Although we have focused on studies of unrelated individuals with quantitative and binary traits, the proposed methods are applicable to other study designs and other traits, such as family studies, extreme-trait sampling, ordinal traits, and (potentially censored) ages at disease onset. In addition, the proposed methods can be extended to incorporate heterogeneous effects among studies by defining the burden statistic as In summary, we developed a simple and practical tool to perform meta-analysis of rare variants based on singlevariant statistics. We showed both theoretically and numerically that the proposed approach has correct type I error and is as powerful as joint analysis of individual participant data (provided that an appropriate reference panel is available). With the GIANT data, we demonstrated that the proposed approach can facilitate the discoveries of rare variants associated with complex human traits.
Appendix A
The joint distributions of ðZ 1 ; .; Z m Þ T for the Wald, score, and LR tests are asymptotically the same. 24 Thus, it suffices to evaluate the covariance matrix of ðZ 1 ; .; Z m Þ T in terms of the correlation matrix of U. Without loss of generality, we center the G i s at their sample mean. In the absence of covariates, Equation 2 reduces to
so the corresponding R is equal to the sample correlation matrix of G. If there exist covariates but they are independent of or weakly correlated with genetic variables, then
where the second equality follows from the centering of the genotype values. Thus, the corresponding R is approximately equal to the correlation matrix of G. In conclusion, two studies with the same LD structure will have essentially the same correlation matrix R if there are no covariates or if the covariates and genetic variables are independent or weakly correlated. We now consider the uncommon situation in which covariates are strongly correlated with genetic variables. For the linear regression analysis of quantitative traits, aðfÞ ¼ s 2 and b 00 ðzÞ ¼ 1. Thus,
This implies that two studies with the same joint distribution of ðG; XÞ will have the same R even when their trait variances ðs 2 Þ are different. For the logistic regression analysis of case-control data,
